10 月 17 日至 21 日，2025年 ESMO 大会在德国柏林召开。荣昌生物在大会上以口头报告形式公布了RC118（CLDN18.2 靶向 ADC）联合 PD1 抑制剂或 RC148（PD1/VEGF 双抗）用于治疗局部晚期或转移性胃及胃食管交界部腺癌（la/m G/GEJA ）的 II 期临床数据（登记号：NCT06038396）。来源：ESMO 官网研究共入组 44 名受试者，其中 42...
Source Link10 月 17 日至 21 日，2025年 ESMO 大会在德国柏林召开。荣昌生物在大会上以口头报告形式公布了RC118（CLDN18.2 靶向 ADC）联合 PD1 抑制剂或 RC148（PD1/VEGF 双抗）用于治疗局部晚期或转移性胃及胃食管交界部腺癌（la/m G/GEJA ）的 II 期临床数据（登记号：NCT06038396）。来源：ESMO 官网研究共入组 44 名受试者，其中 42...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.